SARS-CoV-2 vaccine effectiveness and breakthrough infections in maintenance dialysis patients

Harold J. Manley, Gideon N. Aweh, Caroline M. Hsu, Daniel E. Weiner, Dana Miskulin, Antonia M. Harford, Doug Johnson, Eduardo K. Lacson
doi: https://doi.org/10.1101/2021.12.20.21268124

Article Information

doi 
https://doi.org/10.1101/2021.12.20.21268124
History 
  • December 21, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Harold J. Manley1,*,
  2. Gideon N. Aweh1,
  3. Caroline M. Hsu2,
  4. Daniel E. Weiner2,
  5. Dana Miskulin2,
  6. Antonia M. Harford1,
  7. Doug Johnson1 and
  8. Eduardo K. Lacson1,2
  1. 1Dialysis Clinic Inc., Nashville, TN
  2. 2Division of Nephrology, Tufts Medical Center, Boston, Massachusetts
  1. ↵*Correspondence: Harold J. Manley, PharmD, Dialysis Clinic, Inc., 1633 Church Street, Nashville, TN 37203, Email: Harold.Manley{at}dciinc.org
Back to top
Posted December 21, 2021.
Download PDF

Supplementary Material

Data/Code
Email
SARS-CoV-2 vaccine effectiveness and breakthrough infections in maintenance dialysis patients
Harold J. Manley, Gideon N. Aweh, Caroline M. Hsu, Daniel E. Weiner, Dana Miskulin, Antonia M. Harford, Doug Johnson, Eduardo K. Lacson
medRxiv 2021.12.20.21268124; doi: https://doi.org/10.1101/2021.12.20.21268124
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area